The relationship of visfatin levels with insulin resistance and left ventricular hypertrophy in peritoneal dialysis patients

Renal Failure

Volumn 34, Issue 6, 2012, Pages 732-737

  Karakan, Sebnem ^a   Sezer, Siren ^a   Özdemir Acar, F Nurhan ^a   Haberal, Mehmet ^a  

^a BASKENT UNIVERSITY   (Turkey)

Author keywords

insulin resistance; peritoneal dialysis; visfatin

Indexed keywords

C REACTIVE PROTEIN; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; URIC ACID;

ADULT; AGED; ANTHROPOMETRY; ARTICLE; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BODY MASS; BODY WEIGHT; CARDIOVASCULAR RISK; CHEMICAL ANALYSIS; CHOLESTEROL BLOOD LEVEL; COMPARATIVE STUDY; CONTROLLED STUDY; CORRELATION ANALYSIS; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; INDEPENDENT VARIABLE; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERITONEAL DIALYSIS; PRIORITY JOURNAL; REGRESSION ANALYSIS; STATISTICAL SIGNIFICANCE; SYSTOLIC BLOOD PRESSURE;

ADULT; AGED; ANTHROPOMETRY; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; ECHOCARDIOGRAPHY; FEMALE; HUMANS; HYPERTROPHY, LEFT VENTRICULAR; INSULIN RESISTANCE; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NICOTINAMIDE PHOSPHORIBOSYLTRANSFERASE; PERITONEAL DIALYSIS; REGRESSION ANALYSIS; RISK FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84862183022     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.3109/0886022X.2012.676493     Document Type: Article

References (40)

1. Kahn BB, Flier JS. Obesity and insulin resistance. J Clin Invest. 2000;106:473-481. (Pubitemid 30666380)
2. Fantuzzi G. Adipose tissue, adipokines, and inflammation. J Allergy Clin Immunol. 2005;115:911-919.
3. Fukuhara A, Matsuda M, Nishizawa M, et al. Visfatin: A protein secreted by visceral fat that mimics the effects of insulin. Science. 2005;307:426-430. (Pubitemid 40139988)
4. Berndt J, Kloting N, Kralisch S, et al. Plasma visfatin concentrations and fat depot-specific mRNA expression in humans. Diabetes. 2005;54:2911-2916. (Pubitemid 41401086)
5. Ingelsson E, Larson MG, Fox CS, et al. Clinical correlates of circulating visfatin levels in a community based sample. Diabetes Care. 2007;30:1278-1280. (Pubitemid 46684663)
6. Filippatos TD, Derdemezis CS, Kiortisis DN, et al. Increased plasma levels of visfatin/pre-B cell colony enhancing factor in obese and overweight patients with metabolic syndrome. J Endocrinol Invest. 2007;30(4):323-326. (Pubitemid 47008083)
7. Kenji O, Kiminori Y, Nozomu K, et al. Circulating visfatin level is correlated with inflammation, but not with insulin resistance. Clin Endocrinol (Oxf). 2007;67(5):796-800.
8. Pagano C, Pilon C, Olivieri M, et al. Reduced plasma visfatin/pre-B cell colony-enhancing factor in obesity is not related to insulin resistance in humans. J Clin Endocrinol Metab. 2006;91(8):3165-3170. (Pubitemid 44271773)
9. Takebayashi K, Suetsugu M, Wakabayashi S, Aso Y, Inukai T. Association between plasma visfatin and vascular endothelial function in patients with type 2 diabetes mellitus. Metab Clin Exp. 2007;56:451-458. (Pubitemid 46427838)
10. Adya R, Tan BK, Punn A, Chen J, Randeva HS. Visfatin induces human endothelial VEGF and MMP-2/9 production via MAPK and PI3K/Akt signalling pathways: Novel insights into visfatin-induced angiogenesis. Cardiovasc Res. 2008;78:356-365. (Pubitemid 351556097)
11. Axelsson J, Witasp A, Carrero JJ, et al. Circulating levels of visfatin/ pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD. Am J Kidney Dis. 2007;49:237-244. (Pubitemid 46178402)
12. Wang P, Xu TY, Guan YF, Su DF, Fan GR, Miao CY. Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: Role of nicotinamide mononucleotide. Cardiovasc Res. 2009;81:370-380.
13. Yamawaki H, Hara N, Okada M, Hara Y. Visfatin causes endothelium dependent relaxation in isolated blood vessels. Biochem Biophys Res Commun. 2009;383:503-508.
14. Twardowski ZJ, Nolph KD, Khanna R. Peritoneal equilibration test. Perit Dial Bull. 1987;7:138-147. (Pubitemid 18014430)
15. Matthews DR, Hosker JP, Rudenski AS. Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 1985;28:412-419. (Pubitemid 15018832)
16. Sahn DJ, De Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-mode echocardiography: Results of a survey of echocardiographic measurements. Circulation. 1978;58:1072-1083. (Pubitemid 9091990)
17. Devereux RB, Alonso DR, Lutas EM, et al. Echocardiographic assessment of left ventricular hypertrophy: Comparison to necropsy findings. J Am Coll Cardiol. 1986;57:450-458. (Pubitemid 16119719)
18. Witowski J, Korybalska K, Wisniewska J. Effect of glucose degradation products on human peritoneal mesothelial cell function. J Am Soc Nephrol. 2000;11:729-739. (Pubitemid 30171882)
19. Davies SJ, Phillips L, Naish PF. Peritoneal glucose exposure and changes in membrane solute transport with time on peritoneal dialysis. J Am Soc Nephrol. 2001;12:1046-1051. (Pubitemid 32378346)
20. Holmes C, Shockley T. Strategies to reduce glucose exposure in peritoneal dialysis patients. Perit Dial Int. 2000;20:S37-S41. (Pubitemid 30410554)
21. Mistry CD, Gokal R, Peers E, MIDAS study group. A randomized multicenter clinical trial comparing isosmolar icodextrin with hyperosmolar glucose solution in CAPD. Kidney Int. 1994;46:496-503. (Pubitemid 24253059)
22. Heimburger O, Waniewski J, Werynski A, et al. A quantitative description of solute and fluid transport during peritoneal dialysis. Kidney Int. 1992;41:1320-1332.
23. Desanto NG, Capodicasa G, Senatore R, et al. Glucose utilization from dialysate in patients on CAPD. Int J Artif Organs. 1979;2:119-125.
24. Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int. 1981;19:564-567. (Pubitemid 11120902)
25. DeFronzo RA, Alvestrand A, Smith D, Hendler R, Hendler E, Wahren J. Insulin resistance in uremia. J Clin Invest. 1981;67:563-568. (Pubitemid 11141740)
26. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: A comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-1454. (Pubitemid 40396812)
27. El-Atat FA, Stas SN, McFarlane SI, Sowers JR. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol. 2004;15:2816-2827. (Pubitemid 41103390)
28. Wellen KE, Hotamisligil GS. Inflammation, stress, and diabetes. J Clin Invest. 2005;115:1111-1119. (Pubitemid 40629025)
29. Fortes PC, Mendes JG, Riella MC, Pecoits-Filho R. Carbohydrate metabolism disturbances in non-diabetic patients on peritoneal dialysis [Abstract]. Perit Dial Int. 2006;26(Suppl. 2):S26.
30. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: A regulator of inflammation. Best Pract Res Clin Endocrinol Metab. 2005;19(4):547-566. (Pubitemid 41823815)
31. Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006;91(4):1578-1581.
32. Chen MP, Chung FM, Chang DM, et al. Elevated plasma level of visfatin/pre-B cell colony enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2006;91(1):295-299.
33. Krzyzanowska K, Krugluger W, Mittermayer F, Rahma R, Haider D, Shnawa N. Increased visfatin concentrations in women with gestational diabetes mellitus. Clin Sci. 2006;1:605-609. (Pubitemid 43736123)
34. Díez JJ, Iglesias P, Fernández-Reyes MJ, et al. Serum concentrations of leptin, adiponectin and resistin, and their relationship with cardiovascular disease in patients with end-stage renal disease. Clin Endocrinol (Oxf). 2005;62:242-249. (Pubitemid 40203922)
35. Stenvinkel P, Ketteler M, Johnson RJ, et al. IL-10, IL-6, and TNF-alpha: Central factors in the altered cytokine network of uremia - the good, the bad, and the ugly. Kidney Int. 2005;67:216-233.
36. Erten Y, Ebinç FA, Ebinç H, et al. The relationship of visfatin levels to inflammatory cytokines and left ventricular hypertrophy in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail. 2008;30:617-623.
37. Cottone S, Nardi E, Mule G, et al. Association between biomarkers of inflammation and left ventricular hypertrophy in moderate chronic kidney disease. Clin Nephrol. 2007;67(4):209-216. (Pubitemid 46605370)
38. Pannier B, Guerin AP, Marchais SJ, Metivier F, Safar ME, London GM. Postischemic vasodilation, endothelial activation, and cardiovascular remodeling in end-stage renal disease. Kidney Int. 2000;57(3):1091-1099. (Pubitemid 30434798)
39. London GM, Blacher J, Pannier B, Guérin AP, Marchais SJ, Safar ME. Arterial wave reflections and survival in end-stage renal failure. Hypertension. 2001;38:434-438. (Pubitemid 34225679)
40. Rongvaux A, Shea RJ, Mulks MH, et al. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis. Eur J Immunol. 2002;32:3225-3234. (Pubitemid 35414880)